Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atea, Biovie, Hansa, Inversago, Mebias, Mirum, Netris, Tyra.
Nearing the end of 2022, the COVID-19 pandemic clearly no longer dominates the clinical activity reported by biopharma companies. Overall clinical data tracked by BioWorld is down significantly, as is the proportion focused on the SARS-Cov-2 virus. Therapeutics and vaccines targeting cancer, infectious diseases and neurological disorders, however, remain a stronghold.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Argenx, Gamida, GSK, Innocare, Intelgenx, Junshi, Marker, Palisade, Regeneron, Revive, Takeda.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Caribou, Clarity, Genmab, Immorna, Legend, Okyo, Rhythm, Tetra, Triastek.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apellis, Bioinvent, Carmell, Eli Lilly, Emmaus, Iovance, Iveric, Kempharm, Novavax, Provention, Sanofi.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apim, Blue Water, Iaso, Microvascular,Nona, Nordic Nanovector, Pfizer Replay, Sensei, Umoja, XNK.
An in-depth investigation of the underlying causes of pulmonary symptoms that in some cases persist for months following recovery from the acute stage of COVID-19 has found a distinctive proinflammatory signature in the plasma and airways of affected patients.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astellas, Azura, Cocrystal, Editas, Evaxion, Immunic, Kinevant, Kiora, Organicell, Pfizer, Takeda, Visen, Vyne.
RSS
